



Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbsilpa.com, Web: www.vbsilpa.com

CIN: L85110KA1987PLC008739

08 February 2024

To
Corporate Relationship Department
BSE Limited,
1st Floor, Rotunda Building,
P.J. Towers, Dalal Street,
Mumbai – 400 001.

To
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051.

Dear Sir/Ma'am,

Sub: Outcome of the meeting of Board of Directors of the Company held on 8 February 2024
Ref: Regulation 30 & 33 of SEBI (LODR) Regulations, 2015

BSE- 530549/ Stock Symbol: NSE – SHILPAMED

This is to inform that the Board of Directors of the Company at their meeting held on 08 February 2024 which started at 11:53 AM and concluded at 03:45 PM have inter alia considered and approved

1. The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and nine months ended 31 December 2023. A Copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1
2. To create, offer, issue and allot, such number of fully paid-up Equity Shares and / or Convertible Bonds (CBs), and / or non-convertible instruments and / or any other instruments and / or combination of instruments with or without detachable warrants with a right exercisable by the warrant holders to convert or subscribe to the Equity Shares or otherwise, in registered or bearer form (hereinafter collectively referred to as the "Securities") or any combination of the Securities, in one or more tranches, denominated in Rupee, by way of a Qualified Institutions Placement ("QIP"), through issue of preliminary placement document and placement document in accordance with Chapter VI of the SEBI ICDR Regulations and any other applicable law, and / or to any person including resident or non-resident investors (whether institutions, body corporates, mutual funds, trusts and / or individuals or otherwise), venture capital funds (foreign or Indian), alternate investment funds, foreign portfolio investors (other than individuals, corporate bodies and family offices), qualified foreign investors, insurance companies, pension funds, Foreign Institutional Investors, Indian and / or Multilateral Financial Institutions, Non-Resident Indians, Employees of the Company and / or any other categories of investors, whether they be holders of Equity Shares of the Company or not (collectively called the "Investors") as may be decided by the Board/Fund raising Committee in its discretion, and permitted under applicable laws and regulations, in consultation with the lead managers and/ or underwriter(s)





Innovating for
affordable healthcare

Shilpa Medicare Limited

Corporate & Admin Office :

"Shilpa House", # 12-6-214/A-1, Hyderabad Road,
Raichur-584 135, Karnataka, India

Tel: +91-8532-238704, Fax: +91-8532-238876

Email: info@vbshilpa.com, Web: www.vbshilpa.com

CIN: L85110KA1987PLC008739

and/ or other advisor(s) appointed for such issue, for an aggregate consideration not exceeding Rs. 500 Crores (Rupees Five Hundred Crores Only) in accordance with the applicable laws subject to receipt of all necessary approvals, if and to the extent required.

3. Conducting of postal ballot for seeking approval of the shareholders by way of special resolution for approval for issuance of the Securities.
4. The Board deliberated on the status of Share Subscription and Shareholder's agreement dt 16 November 2023 with Ash Ingredients INC, New Jersey, USA (details of which was duly intimated to the Stock Exchange on the same day) and has decided to withdraw from the said arrangement since the said deal is no longer commercially viable.

This is for your information and necessary records.

For Shilpa Medicare Limited,

Ritu Tiwary

Company Secretary & Compliance Officer





Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Shilpa Medicare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Shilpa Medicare Limited ("the Company") for the quarter ended December 31, 2023 and year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). ("the Statement") attached herewith.
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





4. We draw your attention to note no 8 in respect of unfavourable foreign arbitration award of Rs.35.96 crs dated 22.01.2024 towards breach of contract, interest upto the award date and legal cost awarded to Celtrion Inc, which the company is proposing to challenge based on the legal advice. Hence the management is of the view that no provision is required as of now in respect of this matter in the Financial Statements.

Our opinion is not modified in respect of this matter.

5. Based on our review conducted nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited standalone financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind-AS') specified under sec.133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting principles generally accepted in India, and policies, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Bohara Bhandari Bung And Associates LLP

Chartered Accountants

Firm Regn No.008127S/S200013



CA. Yogesh R. Bung

Partner

M.No.143932

Place: Raichur

Date: 08.02.2024

UDIN: 24143932BKAEJQ9266



Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Shilpa Medicare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Shilpa Medicare Limited ("the Parent"), and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), its associates for quarter ended December 31, 2023, and the consolidated year to date results for the period 1 April 2023 to 31 December 2023, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.





4. The Statement includes the results of the following subsidiaries / Associates / Joint Ventures:

A) Subsidiaries

- i. Shilpa Pharma Lifesciences Limited (formerly known as Shilpa Corporate Holdings Private Limited)
- ii. Shilpa Therapeutics Private Limited
- iii. INM Technologies Private Limited
- iv. INM Nuvent Paints Private Limited (Step down subsidiary)
- v. Shilpa Biologicals Private Limited
- vi. Shilpa Biocare Private Limited (Formerly known as "Shilpa Albumin Private Limited")
- vii. Vegil Labs Private Limited
- viii. Shilpa Lifesciences Private Ltd (Step down subsidiary)
- ix. FTF Pharma Private Limited
- x. Makindus, Inc
- xi. Koanaa Healthcare Limited, UK
- xii. Koanaa Healthcare Limited, Austria
- xiii. Koanna Healthcare Canada Inc
- xiv. Indo Biotech SDN.BHD, Malaysia
- xv. Koanna International FZ-LLC, Dubai
- xvi. Koanna Healthcare, Spain S.L
- xvii. Shilpa Pharma Inc
- xviii. Pilnova Pharma Inc

B) Joint Venture

- i. Reva Medicare Private Limited
- ii. Sravathi Advance Process Technologies Private Limited
- iii. Sravathi AI Technologies Private Limited

C) Associates

- i. MAIA Pharmaceuticals, Inc
- ii. Reva Pharmachem Private Limited
- iii. Auxilla Pharmaceuticals and Research LLP

5. We draw your attention to note no 8 in respect of unfavourable foreign arbitration award of Rs.35.96 crs dated 22.01.2024 towards breach of contract, interest upto the award date and legal cost awarded to Celltrion Inc, which the company is proposing to challenge based on the legal advice. Hence the management is of the view that no provision is required as of now in respect of this matter in the Financial Statements.

Our opinion is not modified in respect of this matter.





6. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. We did not review the interim financial statements of two (02) subsidiaries included in the consolidated unaudited financial results, whose interim financial statements reflect as follows,

Particulars	Quarter ended December 31,2023	9 months ended December 31, 2023
Total Assets	7,521.79	7,521.79
Total Revenue	776.68	2,316.51
Total Net profit/(loss) after tax	28.35	103.92
Total Comprehensive Income	29.40	107.08
Total Cash Flow / (Outflow) (net)	-	(52.62)

The statement also includes Group's share of net profit/ (loss) after tax and total comprehensive profit/ (loss) of Rs. (13.32) and (126.90) Lakhs for the quarter & 9 months ended as at 31st December, 2023, respectively as considered in the statement, in respect of one (01) Associate company.

These above interim financial statements have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, and joint ventures is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters.

8. The accompanying statement includes the unaudited financial results of Nine (09) subsidiaries, whose interim financial results reflects as follows,

Particulars	Quarter ended December 31,2023	9 months ended December 31, 2023
Total Assets	4281.64	4281.64
Total Revenue	270.22	1110.29
Total Net profit/(loss) after tax	(315.20)	(104.45)
Total Comprehensive Income	(315.20)	(104.45)
Total Cash Flow / (Outflow) (net)	-	(23.60)





BOHARA BHANDARI BUNG & ASSOCIATES LLP
CHARTERED ACCOUNTANTS

The unaudited interim financial results and other unaudited financial information of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the statement, in so far as it relates to the affairs of these subsidiaries is based solely on such unaudited interim financial results and other unaudited financial information. According to the information and explanations given to us by the Management, these interim financial information are not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

9. In case of one (01) foreign associate, interim financial statements for the quarter and 9 months ended December 31, 2023 are not concluded and have not been furnished to us by the Management, and our opinion on the Consolidated Financial Statements, in so far as it relates to the amounts included in respect of this associate is based solely on the information available for the period ended September 30, 2023. According to the information and explanations given to us by the Management, this interim financial information is not material to the Group.

Our conclusion on the statement is not modified in respect of the above matter.

For Bohara Bhandari Bung And Associates LLP

Chartered Accountants

Firm Regn No.008127S/S200013



CA.Yogesh .R. Bung

Partner

M.No.143932

Place: Raichur

Date: 08-02-2024

UDIN: 24143932BKAEJR6273



Shilpa Medicare Limited

Registered office: # 12-6-214/A-1, Hyderabad Road, Raichur- 584135

Website - www.vbshilpa.com, Email - info@vbshilpa.com., Telephone -+91-8532-238494

CIN No. - L8510KA1987PLC008739

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Rs. In Lakhs, except per equity share data)

S. No.	Particulars	Quarter ended			Nine months ended		Previous year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
	Continuing Operations:						
1	Income						
	Revenue from operations	6,397.93	7,461.45	5,164.19	22,233.50	18,120.69	24,770.20
	a) Net Sales/Income from operations	3,831.07	4,788.70	4,386.50	12,402.90	15,115.72	21,003.42
	b) Service Income and License fees	2,566.86	2,672.75	777.69	9,830.60	3,004.97	3,766.78
	Other Income	2,232.54	2,276.13	1,759.70	6,586.93	4,831.25	6,864.42
	Total Income	8,630.51	9,737.58	6,923.89	28,820.43	22,951.94	31,634.62
2	Expenses						
	a) Cost of material consumed	1,046.05	2,227.25	1,406.83	4,673.80	4,403.69	6,260.67
	b) Purchase of stock-in-trade	247.91	359.93	69.41	863.35	413.66	1,551.32
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	552.44	(719.84)	(17.10)	140.45	867.95	407.96
	d) Employee benefits expense	2,533.63	2,623.33	2,660.90	7,936.74	8,418.63	11,045.20
	e) Finance cost	260.79	517.81	664.09	1,454.59	1,421.69	2,082.51
	f) Depreciation and amortisation expenses	1,239.38	1,266.73	1,225.73	3,732.40	3,456.87	4,654.75
	g) Other expenses	2,347.70	2,241.72	2,069.70	6,686.00	7,039.74	9,905.15
	Total Expenses	8,227.92	8,516.93	8,079.56	25,487.33	26,022.23	35,907.56
3	Profit before tax and exceptional items (1-2)	402.59	1,220.55	(1155.67)	3,333.11	(3070.29)	(4272.94)
4	Exceptional items- (Income)/Expenses (PI refer note no: 03, 04,05 & 06)	11.83	21.17	-	666.74	58.53	1,554.65
5	Profit Before Tax from continuing operations (3-4)	390.76	1,199.48	(1155.67)	2,666.36	(3128.82)	(5827.59)
6	Tax Expense of continuing operations	121.06	539.22	(676.94)	946.40	(1073.02)	(879.30)
	-Current tax	129.36	592.78	(201.92)	910.17	(730.58)	(836.56)
	-Deferred tax (Net of MAT credit)	(8.30)	(53.56)	(475.02)	36.24	(342.44)	(42.74)
7	Profit for the Period/year from continuing operations (5-6)	269.70	660.26	(478.73)	1,719.96	(2055.80)	(4948.29)
	Discontinued Operations:						
8	Profit/(loss) before tax for the period/year from discontinued operations (refer note no: 07)	-	-	-	-	7,095.22	7,095.22
9	Tax (expense)/credit of discontinued operations	-	-	-	-	3,572.38	3,572.38
10	Profit for the period/year from discontinued operations (8-9)	-	-	-	-	10,667.60	10,667.60
11	Net profit for the period/year (7+10)	269.70	660.26	(478.73)	1,719.96	8,611.80	5,719.31
12	Other comprehensive income (OCI) from continuing operation						
	A. Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the defined benefit (liability)/asset	-	-	-	-	-	283.63
	B. Items that will be reclassified subsequently to profit or loss						
	Gain / (Loss) or derivative instrument (net)	-	-	-	-	-	-
	Total other comprehensive income (net of tax) (A+B)	-	-	-	-	-	283.63
13	Other comprehensive income (OCI) from discontinuing operations						
	A. Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the defined benefit (liability)/asset	-	-	-	-	(144.95)	(144.96)
14	Total other comprehensive income/(expenses) for the period/year from continued operations	269.70	660.26	(478.73)	1,719.96	(2055.80)	(4664.66)
15	Total other comprehensive income/(expenses) for the period/year from discontinued operations	-	-	-	-	10,812.55	10,812.56
15	Total comprehensive income for the period / year (14+15)	269.70	660.26	(478.73)	1,719.96	8,756.75	6,147.90
17	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	868.02	868.02	868.02	868.02
18	Reserves i.e Other equity						2,10,890.38
19	Earnings per equity share (par value Rs.1/- each):	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)
	Continuing Operations:						
	Basic (Rs.)	0.31	0.76	(0.55)	1.98	(2.37)	(5.70)
	Diluted (Rs.)	0.31	0.76	(0.55)	1.98	(2.37)	(5.70)
	Discontinued Operations:						
	Basic (Rs.)	-	-	-	-	12.29	12.29
	Diluted (Rs.)	-	-	-	-	12.29	12.29
	Total Operations:						
	Basic (Rs.)	0.31	0.76	(0.55)	1.98	9.92	6.59
	Diluted (Rs.)	0.31	0.76	(0.55)	1.98	9.92	6.59



STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Rs. In Lakhs, except per equity share data)

Sl No.	Particulars	Quarter ended			Nine months ended		Previous year ended
		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	Revenue from operations	28,648.17	31,297.68	26,249.74	85,963.32	78,655.92	1,05,011.24
	a) Net Sales/Income from operations	24,059.93	26,968.18	24,627.79	70,798.28	72,681.15	96,689.66
	b) Service Income and license fees	4,588.24	4,329.50	1,621.95	15,165.04	5,974.77	8,321.58
	Other Income	221.45	180.85	273.89	595.40	1,522.67	1,739.97
	Total Income	28,869.63	31,478.53	26,523.53	86,558.72	80,178.59	1,06,751.21
2	Expenses						
	a) Cos. of material consumed	10,599.63	12,200.64	8,374.73	32,315.46	28,864.81	37,043.76
	b) Purchase of stock-in-trade	383.90	475.77	(77.44)	1,265.73	2,216.44	3,398.52
	c) Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1337.01)	(97.85)	2,255.27	(2533.60)	1,564.83	1,150.02
	d) Employee benefits expense	6,907.15	7,309.47	6,851.15	21,504.29	21,493.15	28,733.09
	e) Finance cost	2,621.77	2,323.67	1,785.47	6,760.56	4,091.33	5,865.21
	f) Depreciation and amortisation expenses	2,670.92	2,778.96	2,407.34	8,124.48	6,980.82	9,549.50
	g) Other expenses	5,495.01	5,379.93	5,717.27	15,995.28	18,111.12	24,457.70
	Total Expenses	27,346.38	30,370.59	27,314.39	82,432.21	83,322.50	1,10,198.20
3	Profit before share of profit of joint venture and associates, exceptional items and tax (1)-(2)	1,523.25	1,107.94	(790.76)	3,126.50	(3143.91)	(3446.99)
4	Share of Profit / (loss) of Joint venture and associates, net of tax	(106.74)	(190.76)	32.61	(463.81)	(260.28)	(380.97)
5	Profit before tax and exceptional items (3-4)	1,416.51	917.18	(758.15)	2,662.69	(3404.19)	(3827.96)
6	Exceptional items- (Income)/Expenses	-	-	-	-	-	-
7	Profit Before Tax (5+6)	1,416.51	917.18	(758.15)	2,662.69	(3404.19)	(3827.96)
8	Tax Expense	946.42	759.70	(95.83)	1,917.47	(1118.23)	(736.36)
	-Current tax	1,273.16	1,293.69	645.48	3,451.46	2,325.28	3,413.10
	-Deferred tax (Net of MAT credit)	(326.74)	(533.99)	(741.31)	(1533.99)	(3443.51)	(4149.45)
9	Profit for the Period / year before non-controlling interest (7)-(8)	470.09	157.48	(662.32)	745.23	(2285.96)	(3091.60)
10	Share of (loss)/profit attributable to non-controlling interest	(12.03)	3.69	0.34	(8.09)	(157.46)	(156.04)
11	Profit after taxes attributable to owners of the Parent Company for the period / year (9-10)	458.06	161.17	(661.98)	737.14	(2443.42)	(3247.64)
12	Other comprehensive income (OCI)						
	A. Items that will not be reclassified subsequently to profit or loss						
	Remeasurement of the defined benefit liability/asset Gain/(Loss) (net of tax)	1.05	1.05	0.52	3.16	148.49	322.64
	B. Items that will be reclassified subsequently to profit or loss						
	Gain / (Loss) on derivative instrument (net of tax)	-	-	-	-	-	-
	Total other comprehensive income(net of tax)(A+B)	1.05	1.05	0.52	3.16	148.49	322.64
13	Total comprehensive income for the period / year (11)+(12)	459.12	162.22	(661.46)	740.30	(2294.93)	(2925.00)
14	Paid up equity share capital (par Value Rs.1/- each, fully paid)	868.02	868.02	868.02	868.02	868.02	868.02
15	Reserves i.e other equity						1,77,459.68
16	Earnings per equity share (par value Rs.1/- each)						
	Basic (Rs.)	(Not annualised) 0.53	(Not annualised) 0.19	(Not annualised) (0.76)	(Not annualised) 0.85	(Not annualised) (2.81)	(Annualised) (3.74)
	Diluted (Rs.)	0.53	0.19	(0.76)	0.85	(2.81)	(3.74)




Notes:

- The above unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2023 in respect of Shilpa Medicare Limited ("the Company") have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on February 08, 2024. The above results have been subject to limited review by the statutory auditors of the Company. The statutory auditors have expressed an unmodified opinion on the said results.
- These financial results have been prepared in accordance with Indian Accounting Standards ('Ind-AS') notified under section 133 of the Companies Act, 2013 read with the relevant rules there under and in terms of Regulation 33 of SEBI (Listing Obligation and Other Disclosure Requirements) Regulations, 2015 (as amended).
- Exceptional loss in current quarter ended December 31, 2023 of Rs.11.83 Lakhs and previous quarter ended September 30, 2023 of Rs.21.17 Lakhs in standalone continued operations is on account of provision for impairment loss of interest accrued but not received & exchange fluctuation on advance reinstating of Koarna International FZ LLC, Dubai, a wholly owned foreign subsidiary
- Exceptional loss in current nine months ended December 31, 2023 of Rs.666.74 Lakhs in standalone continued operations is on account of provision for impairment losses on account of investment in, advance to and interest accrued but not received from Koarna International FZ LLC, Dubai, a wholly owned foreign subsidiary
- Exceptional loss in previous year nine months ended December 31, 2022 of Rs.58.53 lakhs in continued operations is on account of write off of investment in Zatoria Holdings Ltd, a wholly owned foreign subsidiary which has been struck off in register under the companies law, Republic of Cyprus w.e.f September 23, 2022
- Exceptional loss for the previous year ended March 31, 2023 of Rs.1,554.65 Lakhs in standalone continued operations is on account of:
 - Rs.54.65 Lakhs investment write off in Zatrria Holdings Ltd, a wholly owned foreign subsidiary
 - Rs.1,000.00 Lakhs provision towards impairment losses on account of investment in and advance to Koarna Healthcare GmbH, Austria, a wholly owned foreign subsidiary
 - Rs.500.00 Lakhs provision towards impairment losses on account of investment in and advance to Koarna Healthcare Limited, United Kingdom, a wholly owned foreign subsidiary
- On 30 June, 2022, the Company had completed the transfer of the Company's Active Pharmaceuticals Ingredient (API) business to Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company for a consideration of Rs. 48,630.00 lakhs (Final consideration being Rs.47,228.00 lakhs after making working capital and other customary adjustments during the previous year quarter ended September 30, 2022).

During the previous year quarter ended September 30, 2022, the Company has recalculated the gain on transfer of its API division under slump sale to its wholly owned subsidiary Company. This has resulted in decrease in the earlier recognised gain of Rs.6,292.51 lakhs in the previous year quarter ended June 30, 2022 by Rs.1,054.00 Lakhs. The said gain is exceptional in nature and been disclosed under the discontinued operations in previous year nine months ended December 31, 2022 and previous year ended March 31, 2023 in standalone financials.


Accordingly, results of API business for the previous year's nine months ended December 31, 2022 and previous year ended March 31, 2023 has been disclosed as discontinued operations in the standalone results.

Particulars	INR in Lakhs					
	Quarter ended			Nine months ended		Previous year ended
	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
Total Income from third parties	-	-	-	-	18,545.27	18,545.27
Inter Company sales to units in continuing operations	-	-	-	-	1,221.47	1,221.47
Total Income	-	-	-	-	19,766.74	19,766.74
Total Expense	-	-	-	-	17,910.49	17,910.49
Profit Before tax and exceptional gain from discontinued operation	-	-	-	-	1,856.25	1,856.25
Exceptional gain on disposal of API business	-	-	-	-	5,238.96	5,238.96
Profit before tax from discontinued operations for the period	-	-	-	-	7,095.21	7,095.21
Tax (expense) / credit of discontinued operations	-	-	-	-	3,572.38	3,572.38
Profit for the period from discontinued operations	-	-	-	-	10,667.59	10,667.59

There is Nil tax impact on the Exceptional Gain made from slump sale of one of its business undertakings to its 100% wholly owned subsidiary U/S 47(iv) of the Income Tax Act, 1961

- The ICC International Court of Arbitration, London in terms of its Order dated 22nd January 2024 has pronounced an arbitration award for breach of contract including interest and legal cost aggregating to approx Rs.35.96 crs (\$4.33 Mn) to Celltrion Inc upto 22.01.2024 plus interest till date of payment. The Company is legally advised that it has sufficient grounds to challenge the order at appropriate forum and is proposing to act according to the legal advice and hence the ultimate outcome of the order cannot be determined presently. Therefore, the management is of the view that no provision is deemed necessary as of now in respect of this matter in the Financial Statements and the same is disclosed as a contingent liability.
- The Operating segment of the Company is "Pharmaceuticals", as the Chief Operating Decision Maker reviews business performance at an overall Company level as one segment. Therefore, segment reporting as per Ind-AS 108 is not applicable to the Company.
- Prior period/year figures have been reclassified wherever required to conform to the classification of the current period/year.

For and on behalf of the Board of Directors
Shilpa Medicare Limited


Omprakash Inhani
Chairman
DIN:01301385



Date: 08.02.2024
Place: Raichur